Alcobra’s (ADHD) Buy Rating Reiterated at Cantor Fitzgerald
Alcobra Ltd. (NASDAQ:ADHD)‘s stock had its “buy” rating reaffirmed by equities researchers at Cantor Fitzgerald in a research note issued on Thursday. They currently have a $16.00 price objective on the stock. Cantor Fitzgerald’s target price indicates a potential upside of 246.32% from the stock’s previous close.
Several other equities analysts have also recently commented on the company. WBB Securities cut Alcobra from a “hold” rating to a “sell” rating and reduced their target price for the company from $5.00 to $4.00 in a research note on Monday, September 12th. Goldman Sachs Group Inc. reiterated a “buy” rating on shares of Alcobra in a research note on Thursday, September 1st. Piper Jaffray Cos. reissued an “overweight” rating and set a $10.00 price target on shares of Alcobra in a research report on Tuesday, August 30th. Jefferies Group reissued a “buy” rating on shares of Alcobra in a research report on Thursday, August 25th. Finally, Barclays PLC began coverage on Alcobra in a research report on Monday, August 1st. They set an “equal weight” rating and a $8.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $10.09.
Shares of Alcobra (NASDAQ:ADHD) opened at 4.62 on Thursday. The stock’s market capitalization is $127.34 million. The firm’s 50 day moving average is $4.83 and its 200 day moving average is $4.53. Alcobra has a 12 month low of $3.15 and a 12 month high of $8.78.
Alcobra (NASDAQ:ADHD) last released its earnings results on Tuesday, August 30th. The company reported ($0.21) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.22) by $0.01. On average, equities analysts predict that Alcobra will post ($0.96) earnings per share for the current fiscal year.
Several large investors have recently bought and sold shares of the stock. Stifel Financial Corp raised its stake in Alcobra by 34.2% in the second quarter. Stifel Financial Corp now owns 62,000 shares of the company’s stock valued at $278,000 after buying an additional 15,800 shares in the last quarter. Palo Alto Investors LLC raised its stake in Alcobra by 7.3% in the second quarter. Palo Alto Investors LLC now owns 272,788 shares of the company’s stock valued at $1,225,000 after buying an additional 18,600 shares in the last quarter. VHCP Management LLC raised its stake in Alcobra by 28.7% in the second quarter. VHCP Management LLC now owns 623,313 shares of the company’s stock valued at $2,799,000 after buying an additional 138,813 shares in the last quarter. VHCP Management II LLC raised its stake in Alcobra by 28.7% in the second quarter. VHCP Management II LLC now owns 1,454,402 shares of the company’s stock valued at $6,530,000 after buying an additional 323,902 shares in the last quarter. Finally, Jefferies Group LLC purchased a new stake in Alcobra during the second quarter valued at about $533,000. 73.69% of the stock is currently owned by institutional investors and hedge funds.
Alcobra Company Profile
Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse.
Receive News & Stock Ratings for Alcobra Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcobra Ltd. and related stocks with our FREE daily email newsletter.